WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Monday, July 23, 2007

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ	
☐	L29	L26 and (stent or graft)	183
☐	L28	L26 and (stent or graft)	183
☐	L27	L26 and stent	61
☐	L26	L25 and (implant$5 or angioplasty or coronary or vascular$7)	508
☐	L25	L24 and (controlled release or sustained release or delayed release or extended release)	762
☐	L24	L23 and (acrylate or polyurethane or polysiloxane or polycarbonate)	4374
☐	L23	$66indazole	13002
☐	L22	indazole	11604
☐	L21	WO-200210137$.did.	11
☐	L20	200210137.pn.	3
☐	L19	20020103229.pn. or wo-200210137$.did. or 200210137.pn.	14
☐	L18	6288089.pn. or 6307056.pn. or 6855719.pn. or 6784174.pn.	8
☐	L17	wo-200056738$.did.	1
☐	L16	wo-200114375$.did.	1
☐	L15	wo-200039101$.did.	1
☐	L14	wo-0039101$.did.	0
☐	L13	L12 and l10	2
☐	L12	terminal kinase inhibitor	95
☐	L11	L10 and kinase inhibitor	19
☐	L10	zeldis-Jerome$.in.	151
☐	L9	zeldis-Zerome$.in.	0
☐	L8	c-Jun N-terminal kinase inhibitor	51
☐	L7	stent same JNK! inhibitor	2
☐	L6	20050019366.pn.	2
☐	L5	20040136937.pn.	2
☐	L4	6103255.pn. or 5607474.pn.	5
☐	L3	(6171610 or 5456917).pn.	4
☐	L2	silicon dioxide with pharmaceutical	1543
☐	L1	(6475530 or 6692764 or 5326569 or 6251457).pn. or 5217997.pn.	10

END OF SEARCH HISTORY

10749344

FILE 'CA, CAPLUS, USPATFULL' ENTERED AT 11:38:40 ON 23 JUL 2007

FILE 'CA, CAPLUS, USPATFULL' ENTERED AT 11:38:55 ON 23 JUL 2007

```
L8            30 S L7
L9         33790 S STENT
L10            0 S L9 AND L8

=> s l8 and carrier
L11           12 L8 AND CARRIER

=> s l11 and polymer
L12            1 L11 AND POLYMER

=> d hitstr abs ibib l12
```

L12 ANSWER 1 OF 1 USPATFULL on STN

IT 395100-04-6
(JNK inhibitors for treatment of central nervous system injury)

RN 395100-04-6 USPATFULL

CN 1H-Indazole, 3-(4-fluorophenyl)-5-(1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



AB Methods of treating, preventing and/or managing a central nervous system injury/damage and related syndromes are disclosed. Specific methods encompass the administration of a JNK inhibitor alone or in combination with a second active agent. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:144661 USPATFULL

TITLE: Methods and compositions using JNK inhibitors for treatment and management of central nervous system injury

INVENTOR(S): Zeldis, Jerome B., Princeton, NJ, UNITED STATES
Faleck, Herbert, West Orange, NJ, UNITED STATES
Manning, Donald C., Bloomsbury, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006122179	A1	20060608	
APPLICATION INFO.:	US 2005-286128	A1	20051122	(11)

	NUMBER	DATE

10749344

PRIORITY INFORMATION:	US 2004-630598P	20041123 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2465	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Blessing Fubara

10749344

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
IT 914910-63-7P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(solid forms of indazolyltriazole as Jun N-terminal kinase inhibitor)
RN 914910-63-7 CAPLUS
CN 1H-Indazole, 3-[3-[2-(1-piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-3-yl)-, compd. with heptane (5:2) (9CI) (CA INDEX NAME)

CM 1

CRN 395104-30-0
CMF C22 H24 N6 O



CM 2

CRN 142-82-5
CMF C7 H16

Me— $(CH_2)_5$ —Me

ACCESSION NUMBER: 2006:1204180 CAPLUS
DOCUMENT NUMBER: 145:511650
TITLE: Solid forms of a indazolyltriazole as Jun N-terminal kinase inhibitor
INVENTOR(S): Saindane, Manohar; Ge, Chuansheng
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 78pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006258706	A1	20061116	US 2006-414630	20060427
WO 2006130297	A2	20061207	WO 2006-US17057	20060427
WO 2006130297	A3	20070215		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,

Blessing Fubara

VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-676693P P 20050429

AB The present invention provides solid forms of 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy)benzene (I), pharmaceutical compns. thereof, and methods for the treatment or prevention of diseases including, but not limited to a liver disease, cancer, a cardiovascular disease, a metabolic disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension, ischemia/reperfusion injury, central nervous system injury/damage or a disease treatable or preventable by the inhibition of Jun N-terminal kinase. In particular, the invention relates to certain novel crystal forms of I. I was prepared in a series of steps starting from 3-hydroxybenzaldehyde and N-(2-2hloroethyl)piperidine-HCl. Different crystal forms of I were prepared by using different solvents.

L3 ANSWER 2 OF 3 CA COPYRIGHT 2007 ACS on STN

IT 914910-63-7P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(solid forms of indazolyltriazole as Jun N-terminal kinase inhibitor)

RN 914910-63-7 CA

CN 1H-Indazole, 3-[3-[2-(1-piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-3-yl)-, compd. with heptane (5:2) (9CI) (CA INDEX NAME)

CM 1

CRN 395104-30-0
CMF C22 H24 N6 O



CM 2

CRN 142-82-5
CMF C7 H16

Me—$(CH_2)_5$—Me

ACCESSION NUMBER: 145:511650 CA
TITLE: Solid forms of a indazolyltriazole as Jun N-terminal kinase inhibitor
INVENTOR(S): Saindane, Manohar; Ge, Chuansheng
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 78pp.

10749344

CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006258706	A1	20061116	US 2006-414630	20060427
WO 2006130297	A2	20061207	WO 2006-US17057	20060427
WO 2006130297	A3	20070215		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-676693P P 20050429

AB The present invention provides solid forms of 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy)benzene (I), pharmaceutical compns. thereof, and methods for the treatment or prevention of diseases including, but not limited to a liver disease, cancer, a cardiovascular disease, a metabolic disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension, ischemia/reperfusion injury, central nervous system injury/damage or a disease treatable or preventable by the inhibition of Jun N-terminal kinase. In particular, the invention relates to certain novel crystal forms of I. I was prepared in a series of steps starting from 3-hydroxybenzaldehyde and N-(2-2hloroethyl)piperidine-HCl. Different crystal forms of I were prepared by using different solvents.

L3 ANSWER 3 OF 3 USPATFULL on STN
IT 914910-63-7P
(solid forms of indazolyltriazole as Jun N-terminal kinase inhibitor)
RN 914910-63-7 USPATFULL
CN 1H-Indazole, 3-[3-[2-(1-piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-3-yl)-, compd. with heptane (5:2) (9CI) (CA INDEX NAME)

CM 1

CRN 395104-30-0
CMF C22 H24 N6 O



Blessing Fubara

10749344

CM 2

CRN 142-82-5
CMF C7 H16

Me— $(CH_2)_5$ —Me

ACCESSION NUMBER:	2006:302346 USPATFULL
TITLE:	Solid forms of a JNK inhibitor
INVENTOR(S):	Saindane, Manohar, Monmouth Junction, NJ, UNITED STATES Ge, Chuansheng, Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006258706	A1	20061116	
APPLICATION INFO.:	US 2006-414630	A1	20060427	(11)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2005-676693P	20050429	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
NUMBER OF CLAIMS:	55
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	52 Drawing Page(s)
LINE COUNT:	2362

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides solid forms of Compound (I), pharmaceutical compositions thereof, and methods for the treatment or prevention of diseases including, but not limited to a liver disease, cancer, a cardiovascular disease, a metabolic disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension, ischemia/reperfusion injury, central nervous system (CNS) injury/damage or a disease treatable or preventable by the inhibition of JNK. In particular, the invention relates to certain novel crystal forms of the compound 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy)benzene.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Blessing Fubara